Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk by Farsang, Csaba
© 2011 Farsang, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 605–622
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
605
ReView
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/VHRM.S23468
indications for and utilization of angiotensin 
receptor ii blockers in patients at high 
cardiovascular risk
Csaba Farsang
Cardiometabolic Center,  
Department of internal Medicine,  
St imre Hospital, Budapest, Hungary
Correspondence: Csaba Farsang 
St imre Hospital Cardiometabolic  
Centre, Department of internal  
Medicine, 1115 Budapest Xi,  
Tétényiu 12-15, Hungary 
Tel +36 1 464 8722 
Fax +36 1 210 6549 
email hunghyp@t-online.hu
Abstract: The worldwide burden of cardiovascular disease is growing. In addition to 
lifestyle changes, pharmacologic agents that can modify cardiovascular disease processes 
have the potential to reduce cardiovascular events. Antihypertensive agents are widely used 
to reduce the risk of cardiovascular events partly beyond that of blood pressure-lowering. In 
particular, the angiotensin II receptor blockers (ARBs), which antagonize the vasoconstrictive 
and proinflammatory/pro-proliferative effects of angiotensin II, have been shown to be cardio 
vascularly protective and well tolerated. Although the eight currently available ARBs are all 
indicated for the treatment of hypertension, they have partly different pharmacology, and 
their pharmacokinetic and pharmacodynamic properties differ. ARB trials for reduction of 
cardiovascular risk can be broadly categorized into those in patients with/without hypertension 
and additional risk factors, in patients with evidence of cardiovascular disease, and in patients 
with severe cardiovascular disease, such as heart failure. These differences have led to their 
indications in different populations. For hypertensive patients with left ventricular hypertrophy, 
losartan was approved to have an indication for stroke prevention, while for most patients 
at high-risk for cardiovascular events, telmisartan is an appropriate therapy because it has a 
cardiovascular preventive indication. Other ARBs are indicated for narrowly defined high-risk 
patients, such as those with hypertension or heart failure. Although in one analysis a possible 
link between ARBs and increased risks of cancer has surfaced, several meta-analyses, using 
the most comprehensive data available, have found no link between any ARB, or the class as a 
whole, and cancer. Most recently, the US Food and Drug Administration completed a review 
of the potential risk of cancer and concluded that treatment with an ARB medication does not 
increase the risk of developing cancer. This review discusses the clinical evidence supporting 
the different indications for each of the ARBs and the outstanding safety of this drug class.
Keywords: angiotensin II receptor blocker, cardiovascular disease, cardiometabolic risk, 
cardiovascular prevention
Introduction
Cardiovascular disease is the major cause of death worldwide, and the number of global 
cardiovascular disease-related deaths is expected to increase from 16.7 million in 2002 
to an estimated 23.3 million in 2030.1 Ischemic heart disease and cerebrovascular 
disease, the most common forms of cardiovascular disease, rank as the two leading 
causes of death worldwide, a trend that is driven by the prevalence rates in high-
income and middle-income countries.1 It is only in low-income countries that 
human immunodeficiency virus/acquired immune deficiency syndrome replaces 
cerebrovascular disease as the second leading cause of death, although ischemic Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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heart disease still remains the leading cause even in these 
countries.1 These global rankings for cardiovascular 
disease are unlikely to change between now and 2030.1 
Cardiovascular disease is a major burden in terms of the 
personal cost to patients resulting from cardiovascular disease 
morbidity-related loss of quality of life and the economic 
costs of the associated health care to society. For example, 
the estimated total costs of cardiovascular disease for 2010 in 
the US was $503.2 billion, of which $76.6 billion was due 
to hypertension alone.2 Similarly, cardiovascular disease 
is the main cause of mortality and morbidity in the European 
Union, costing the European Union economy €169 billion 
in 2003, of which around 62% was due to health care costs.3 
The UK has particularly high total costs for cardiovascular 
disease (€36.5 billion), accounting for 22% of the total 
European Union costs.3 A separate study found that the total 
cardiovascular disease costs in the UK were £29.1 billion 
in 2004, with coronary heart disease and cerebrovascular 
disease accounting for 29% and 27% of the total costs, 
respectively.4 The UK spends approximately 18% of its total 
health care expenditure on cardiovascular disease, the highest 
proportion of any European Union country.4
There is a clear clinical and economic need to reduce 
the rate of cardiovascular disease, but this is challenging for 
a number of reasons, including the ever-increasing size of 
the elderly population and the growing burden of lifestyle-
related diseases, such as obesity and diabetes mellitus, both 
known risk factors for cardiovascular disease. Although 
patients can do much to improve their cardiovascular disease 
risk profile by adopting nonpharmacologic interventions 
(eg, weight loss, dietary changes, smoking cessation), 
pharmacologic agents that can modify the disease processes 
involved in cardiovascular disease progression may play a 
crucial role in reducing the burden of cardiovascular disease. 
Hypertension is a well known risk factor for microvascular 
and macrovascular disease, and there is considerable evidence 
that lowering blood pressure reduces these risks.5 The renin-
angiotensin system plays a crucial role in the development of 
hypertension and cardiovascular disease via the production of 
angiotensin II, which induces not only acute vasoconstriction 
by binding mainly to the angiotensin II type 1 receptor 
(AT1) but also promotes vascular growth and proliferation, 
and endothelial dysfunction, leading to cardiovascular 
disease.6 Angiotensin II has multiple biological effects in 
addition to modulating blood pressure, including acting as a 
proinflammatory mediator at all stages of the cardiovascular 
and renal disease continua, which makes it an important target 
for intervention.7–9
Blockade of the renin-angiotensin system is achieved 
by a number of agents that work by either inhibiting the 
effects of renin (direct renin inhibitors), conversion of angio-
tensin I to angiotensin II (angiotensin-converting enzyme 
[ACE] inhibitors), or by blocking the binding of angiotensin 
II to the AT1 receptor (angiotensin II receptor blockers 
[ARBs], Figure 1). ACE inhibitors and ARBs now form 
part of the large arsenal of routinely used antihypertensive 
agents with cardioprotective effects beyond that of lowering 
blood pressure,10–13 and the first-in-class direct renin inhibitor, 
aliskiren, was approved for use in hypertension in the US 
and Europe in 2007. Direct renin inhibitors decrease plasma 
renin activity and inhibit the conversion of angiotensinogen 
to angiotensin I. Currently, there is limited evidence of any 
beyond blood pressure-lowering effects with the direct renin 
inhibitors, although a study has demonstrated that aliskiren is 
as effective as the ARB losartan in promoting left ventricular 
mass reduction in hypertensive patients.14 As beyond blood 
pressure-lowering evidence is lacking for the direct renin 
inhibitors, this class of agent will not be discussed further in 
this review, but the results of ongoing clinical trials for this 
drug class are awaited.15
The cardiovascular disease and renal pathophysiologic 
continua describe a chain of events, starting with hypertension, 
diabetes, dyslipidemia, and other risk factors (such as obesity 
and smoking), progressing through atherosclerosis, left 
ventricular hypertrophy, coronary artery disease, myocardial 
infarction, stroke, renal insufficiency and peripheral arterial 
insufficiency, and ultimately end-stage heart disease (left 
ventricular dysfunction and heart failure) and end-stage 
renal disease.7,16 This review examines the evidence that the 
ARBs are able to affect cardiovascular disease processes 
mediated by angiotensin II throughout the cardiovascular 
and renal disease continua. Large trials of ARBs with 
cardiovascular and renal endpoints were identified initially 
by reviewing recent guidelines, guideline updates, and other 
authoritative reviews. This was supplemented by targeted 
keyword searches on PubMed to identify relevant preclinical 
and clinical studies.
Effects of renin-angiotensin system 
blockade beyond lowering blood 
pressure
Blockade of the renin-angiotensin system reduces cardio-
vascular disease progression and end-organ damage not only 
by reducing blood pressure, but also by opposing the proin-
flammatory effects of angiotensin II.8 Both ARBs and ACE 
inhibitors have been investigated extensively for their effects Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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on cardiovascular risk beyond blood pressure control alone 
in a very wide range of patients across the cardiovascular 
and renal disease continua.17–29
The beneficial effect of ACE inhibitors and ARBs 
results mainly from their blockade of the renin-angiotensin 
system, which not only directly reduces blood pressure, 
thus reducing the impact of this cardiovascular disease 
risk factor, but also reduces the proinflammatory effects of 
angiotensin II.   Conversion of angiotensin I to angiotensin II 
is not completely blocked by ACE inhibitors because many 
other enzymatic pathways (eg, chymase, cathepsin, tonin, 
chymostatin-sensitive Ang II-generating enzyme, tissue-type 
plasminogen activator) exist, which can lead to the so-called 
“angiotensin escape phenomenon,” eg, a gradual return to 
pathologic levels of angiotensin II.30
Bradykinin degradation is also inhibited by ACE 
  inhibitors, which can further enhance the vasodilatory effects 
of this mechanism of renin-angiotensin system blockade,31 
but it is also thought to be involved in the pathology of the 
side effects (dry cough, angioedema).32 In addition to block-
ing the actions of angiotensin II that are mediated by the AT1 
receptor, ARBs may also promote end-organ protection by 
leaving the AT2 receptor free to be activated by angiotensin II. 
AT2 receptor activation is thought to have the opposite effect 
of those mediated by the AT1 receptor, which are beneficial 
to the cardiovascular system and help protect target organs 
from damage.33
This potential to provide additional pleiotropic effects 
beyond those achieved by blood pressure-lowering alone 
has led to the use of renin-angiotensin system blockade in 
patients whose hypertension is compromised by the presence 
of additional cardiovascular disease risk factors, although it 
should be noted that there is debate over the degree to which 
these agents confer further benefits above those provided by 
simply lowering blood pressure.13,34,35 ARBs are often used 
in patients who are intolerant of ACE inhibitors due to the 
development of cough or angioedema,36–38 or in those who 
are at a high risk of developing either of these side effects. 
Patients over 60 years, females, those of east-Asian ethnicity 
and smokers are at increased risk of cough, and patients 
of African-American ethnicity, smokers, or those patients 
with a history of ACE inhibitor cough are at increased risk 
of angioedema.39 Although the available evidence suggests 
that ACE inhibitors and ARBs have similar blood pressure-
lowering effects,40 ARBs are better tolerated than ACE 
inhibitors and other antihypertensive agents in both the short 
term and the long term.41 This is an important   benefit, because 
hypertension is often asymptomatic, making long-term 
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Figure 1 Scheme of the renin-angiotensin system. 
Abbreviations: ACe, angiotensin-converting enzyme; ARB, angiotensin ii receptor blockers; NO, nitric oxide; SNS, sympathetic nervous system; tPA, tissue plasminogen 
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treatment adherence a challenge. However, the ARBs are 
not all equally effective. This review describes the intraclass 
  differences in pharmacology and efficacy of the different 
ARBs, and how this translates into clinical benefit. Patients 
must be assessed thoroughly to determine their correct 
cardiovascular disease risk level so that the most appropriate 
ARB-based treatment can be selected.
ARBs: important differences in 
pharmacology and clinical efficacy
Pharmacology
There are eight ARBs currently on the market for hypertension 
and in different cardiovascular indications, ie, azilsartan, 
candesartan, eprosartan, irbesartan, losartan, olmesartan, 
telmisartan, and valsartan. The ARBs demonstrate 
considerable differences in their pharmacology, and these 
differences are likely to affect their clinical efficacy. Most 
ARBs share a common tetrazolo-biphenyl structure based 
on losartan.42,43 In contrast, telmisartan has a novel bis-
benzimidazole structure, while eprosartan is a non-biphenyl 
non-tetrazole ARB.44 These differences in molecular 
structure lead to differences in the pharmacokinetic 
and pharmacodynamic properties of the ARBs, such 
as lipophilicity, volume of distribution, bioavailability, 
biotransformation, plasma half-life, receptor affinity, and 
residence time, elimination, and some specific pleiotropic 
effects (Table 1).45–47 For example, candesartan, eprosartan, 
irbesartan, olmesartan, telmisartan, and the active metabolite 
of losartan are all noncompetitive (insurmountable) AT1 
antagonists. They suppress the agonist response despite 
escalations in agonist concentration.45,48 Whether this 
translates into more effective protection from the effects of 
angiotensin II remains unknown. Of the ARBs, telmisartan 
has the highest affinity for the AT1 receptor and the longest 
receptor dissociation half-life,49 properties that are likely to 
be responsible for its long-lasting antihypertensive effects. 
Telmisartan also has the lowest half-maximal inhibitory 
concentration of any ARB, including the new ARB, 
azilsartan.50 Telmisartan is also the most lipophilic of the 
ARBs, which facilitates oral absorption and probably deep 
tissue and cellular penetration, and results in the highest 
volume of distribution of approximately 500 L (7 L/kg).46,51 
Irbesartan demonstrates the highest oral bioavailability of 
the ARBs at 60%–80%, and eprosartan has the lowest.45 
None of the ARBs interact with food, which makes oral 
administration very straightforward for this class of agents. 
The half-lives of the ARBs vary considerably, with valsartan 
at approximately seven hours and telmisartan having the 
longest, at approximately 24 hours.46,52,53 These half-life 
characteristics have implications for the duration of their 
therapeutic effects. Several of the ARBs, irbesartan and 
losartan, are metabolized by cytochrome P450 (CYP), and 
are therefore subject to potential drug-drug interactions 
with other drugs that alter CYP activity.54 Telmisartan 
can result in elevated serum digoxin in some patients.55 
Clinically significant drug interactions are unlikely with 
either irbesartan or telmisartan,56 although CYP inducers 
(such as rifampicin and grapefruit juice) may interact 
significantly with losartan.56 In contrast with some of the 
ARBs, telmisartan is metabolized only via glucuronidation 
and almost entirely eliminated in the feces (.98%), so renal 
impairment is unlikely to affect the pharmacokinetics of 
this ARB.46
A number of the ARBs exert multiple “pleiotropic” 
biological effects in addition to those mediated via the AT1 
receptor that are worthy of special mention. However, the role 
these pleiotropic effects may play in cardiovascular disease 
prevention remains unclear. All ARBs appear to be able to 
Table 1 Comparative pharmacokinetic properties of angiotensin ii receptor blockers43,128
Drug tmax (h) Bioavailability (%) t½ (h) Vd (L) Interaction  
with food
Elimination 
(feces/urine)
Losartan 1 (3–4)* 33 2 (4–6)* 34 (12)* No 60/35
Valsartan 2 23 7 17 No 83/13
irbesartan 1–2 60–80 12–20 53–93 No 80/20
Candesartan 3–5 42 9–13 0.13 L/kg No 67/33
eprosartan 2–6 13 5–7 308 No 90/10
Telmisartan 1 43 24 500 No .98% fecal
Olmesartan 1.4–2.8 26† 11.8–14.7 14.7–19.7 No 35%–49% urinary 
recovery rate‡
Azilsartan 1.5–3 60 11 16 No 55/42
Notes: *Values in parentheses are for eXP 3174, the active metabolite of losartan; †olmesartan medoxomil; ‡intravenous olmesartan. 
Abbreviations: PK, pharmacokinetic; ARB, angiotensin ii receptor blocker; t½, terminal elimination half-life; tmax, time to maximum plasma concentration; Vd, volume of 
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penetrate the cell nucleus and partially activate peroxisome 
proliferator-activated receptor gamma (PPARγ), which in 
turn influences the expression of genes involved in carbohy-
drate and lipid metabolism;46,57 however, telmisartan is the 
only ARB shown to be able to activate PPARγ at therapeutic 
dosages.58 A range of metabolic effects has been studied, such 
as insulin resistance, dyslipidemia, and blood glucose regula-
tion, and, in general, telmisartan produces greater beneficial 
effects on glucose metabolism than the other ARBs.46 This 
additional activity of telmisartan may mean that this agent 
possibly affects the underlying biochemical features of the 
metabolic syndrome that increase the risk of diabetes and 
cardiovascular disease in high-risk populations.57 However, 
whether the PPARγ agonist effect could be clinically valuable 
in prevention of new-onset diabetes is still debated, because 
in the ONgoing Telmisartan Alone and in combination with 
Ramipril Global Endpoint Trial (ONTARGET®) there were 
no fewer cases of new-onset diabetes with telmisartan than 
with ramipril.28 Other ARB-specific pleiotropic effects have 
been reported. Azilsartan has been demonstrated to reduce 
plasminogen activator inhibitor type-I expression in the aortic 
walls of mice, which may limit the progression of athero-
sclerotic plaques that are at risk of rupture.58 Candesartan has 
been found to reduce redox-sensitive NF-κB-mediated renal 
inflammation independently of AT1 receptors, although not 
at therapeutic doses.59 Losartan inhibits urate transporter 1, 
thereby reducing serum uric acid levels.60 Serum uric acid 
appears to be an important, probably independent, risk factor 
for cardiovascular disease and renal disease, particularly in 
patients with hypertension.61 Evidence from the Losartan 
Intervention for Endpoint reduction in hypertension (LIFE) 
study demonstrated that the increase in serum uric acid over 
4.8 years was reduced by losartan compared with atenolol and 
that this reduction appeared to explain 29% of the beneficial 
effect that losartan had on the primary composite endpoint of 
cardiovascular death, fatal or nonfatal myocardial infarction, 
and fatal or nonfatal stroke.62
Clinical efficacy of the ARBs
Studies in patients with hypertension
Pharmacokinetic factors, including bioavailability, volume 
of distribution, elimination half-life, and AT1 receptor 
interactions, all impact on the antihypertensive potency of 
the individual ARBs. A systematic review of studies that 
had used 24-hour ambulatory blood pressure measurements 
demonstrated significant differences between the ARBs 
studied in terms of 24-hour mean blood pressure   reductions.63 
However, these studies were mostly not direct   comparisons, 
and also varied in doses employed and study designs. 
Direct comparisons are required to judge relative efficacy 
  conclusively. For example, direct comparisons of olmesar-
tan with other ARBs, several of them conducted since the 
review,63 have found it to give blood pressure reductions 
superior to losartan,64–66 and either superior,64,65 similar,67 or 
inferior68 to valsartan, while two small studies have found 
it to be inferior to telmisartan.69,70 Azilsartan, at its maximal 
dose, produced superior 24-hour ambulatory blood pressure 
reductions compared with olmesartan and valsartan at their 
maximal approved doses.71,72 All of the ARBs are associated 
with favorable tolerability profiles, which probably explains 
the enhanced persistence and treatment adherence with these 
agents compared with all other classes of antihypertensive 
agents.41,73
Primary and secondary prevention trials have demonstrated 
that, in addition to reducing blood pressure effectively, many 
of the ARBs reduce both cardiovascular disease progression 
and events, although few direct comparative studies of the 
ARBs in cardiovascular disease prevention exist. However, 
when considering trial data, it is crucial to consider the 
characteristics of the study population. ARB cardiovascular 
and renal outcome trials have been conducted in patients 
at different stages in the cardiovascular and renal disease 
continua: hypertension and early-stage cardiovascular 
disease; with or without hypertension but at an increased 
cardiovascular risk due to a prior cardiovascular disease event 
or the presence of diabetes; and with cardiovascular disease, 
left ventricular dysfunction, and heart failure.
The next section of this review presents data from the 
most important clinical trials that have studied ARBs in 
patients at the various stages along the cardiovascular and 
renal disease continua (Table 2).19–22,24,27–29,74–85,88–96 Although 
there are similarities between these patient populations, there 
are also important differences, particularly those with heart 
failure, who tend to be older and who usually present with 
several comorbidities.86 Therefore, we will consider the 
evidence for the different groups separately.
Studies in hypertensive patients  
and other risk factors
There have been a number of studies of cardiovascular 
disease and renal outcomes with ARBs conducted in patients 
at the relatively early stages of the cardiovascular disease 
continuum, ie, patients with hypertension and other risk 
factors for cardiovascular disease, such as type 2 diabetes 
with renal disease. The LIFE study randomized 9193 patients 
with hypertension and left ventricular hypertrophy to Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Patient characteristics and findings from selected outcomes trials of angiotensin II receptor blockers in patients at different 
stages of the cardiovascular and renal disease continua17–20,22,25–27,67–78
Study Patient characteristics Treatments Primary outcomes
Studies in patients with hypertension and other complications
LiFe22 Patients aged 55–80 years,  
with essential hypertension  
and LVH; n = 9193
Losartan- or atenolol-based 
antihypertensive regimen;  
mean follow-up: 4.8 years
Significant reduction in composite endpoint 
of CV death, Mi, or stroke with losartan-
based regimen versus atenolol-based 
regimen
VALUe74 Patients aged $50 years,  
with hypertension and a high risk  
of cardiac events based on the  
presence qualifying risk factors;  
n = 15,313
Valsartan- or amlodipine-based 
antihypertensive regimen;  
mean follow-up: 4.2 years
No significant difference between treatments 
for the composite endpoint of cardiac 
morbidity and mortality. Amlodipine 
demonstrated superior efficacy compared 
with valsartan on the incidence of Mi, which 
was most likely a BP-related effect
The Kyoto Heart  
Study75
Patients aged $20 years,  
with uncontrolled hypertension  
and high CV risks; n = 3031
Valsartan- or non-ARB-based 
antihypertensive regimen;  
median follow-up 3.27 years
Significant reduction in the composite 
endpoint of fatal and nonfatal CV events with 
the valsartan-based regimen versus the non-
ARB-based regimen. Relatively soft endpoints 
driving the results and the open-label design 
have been a source of criticism
iRMA220 Patients aged 30–70 years,  
with T2DM, hypertension  
and persistent microalbuminuria;  
n = 590
irbesartan or placebo on a  
background of antihypertensive 
treatment; median follow-up  
2.0 years
Significant reduction in the primary endpoint 
of a UAe rate .200 μg/min that was  
30% higher than baseline with irbesartan  
vs placebo. Findings confirmed in a substudy 
using 24-hour ABPM61
ReNAAL21 Patients aged 31–70 years,  
with T2DM, hypertension and  
diabetic nephropathy; n = 1513
Losartan or placebo on a  
background of antihypertensive 
treatment; mean follow-up  
3.4 years
Significant reduction in the primary 
composite endpoint of a doubling of the 
baseline serum creatinine concentration, the 
development of eSRD, or all-cause mortality 
with losartan vs placebo (-16%)
iDNT19 Patients aged 30–70 years,  
with T2DM, hypertension and  
diabetic nephropathy; n = 1715
irbesartan or amlodipine or  
placebo on a background of 
antihypertensive treatment;  
mean follow-up 2.6 years
Significant reduction in the primary 
composite endpoint of a doubling of the 
baseline serum creatinine concentration, the 
development of eSRD or all-cause mortality 
with irbesartan vs amlodipine (-23%) and 
with irbesartan vs placebo (-20%)
DeTAiL®24 Patients aged 35–80 years,  
with T2DM, mild to moderate 
hypertension and early  
nephropathy; n = 250
Telmisartan or enalapril on a 
background of antihypertensive 
treatment; mean/median  
follow-up not available
equivalent reduction in the primary endpoint 
of the change in the GFR from baseline 
during 5 years of treatment with telmisartan 
vs enalapril
AMADeO®27 Patients aged 21–80 years,  
with T2DM, hypertension, or  
on antihypertensive drugs and  
overt nephropathy; n = 860
Telmisartan or losartan on a 
background of antihypertensive 
treatment mean follow-up  
0.89 years
Significant reduction in the primary endpoint 
of the difference in the urinary albumin to 
creatinine ratio from baseline to week 52 
with telmisartan vs losartan despite similar 
BP reductions in the 2 groups
ViVALDi®77 Patients aged 30–80 years,  
with T2DM, hypertension and  
overt nephropathy; n = 885
Telmisartan or valsartan on a 
background of antihypertensive 
treatment mean/median  
follow-up not available
equivalent reductions in the primary 
endpoint of the change from baseline in 
the 24-hour proteinuria after 12 months 
for telmisartan and valsartan. Greater 
renoprotection was seen in those patients 
with better BP control
Studies in high-risk patients with a broad range of risk factors
ONTARGeT28 High-risk patients aged $55 years,  
with coronary, peripheral, or  
cerebrovascular disease or  
diabetes with end-organ damage;  
n = 25,620
Telmisartan-, ramipril- or  
telmisartan plus ramipril-based 
antihypertensive regimens;  
median follow-up 4.7 years
Telmisartan was equivalent to ramipril 
for the primary composite endpoint of 
CV death, Mi, stroke, or hospitalization 
due to HF, but it was associated with less 
angioedema and better treatment adherence. 
The combination was associated with more 
adverse events without an increase in efficacy
(Continued)Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
611
ARBs in patients at high CV risk
Table 2 (Continued)
Study Patient characteristics Treatments Primary outcomes
TRANSCeND29 High-risk patients aged $55 years,  
with coronary, peripheral, or  
cerebrovascular disease or  
diabetes with end-organ damage,  
and intolerant to ACe inhibitors;  
n = 5926
Telmisartan regimen or placebo- 
based regimen (on a background  
of other antihypertensive agents);  
median follow-up 4.7 years
equivalent reduction in the primary 
composite endpoint of CV death, Mi, stroke, 
or hospitalization for HF with telmisartan 
vs placebo. Significant reduction in the 
secondary composite endpoint of CV death, 
Mi, or stroke with telmisartan (13%; HR 
0.87) vs placebo (14.8%)
ROADMAP93 High-risk patients with type 2  
diabetes and at least one  
additional cardiovascular risk  
factor, but no evidence of renal 
dysfunction; n = 4447
Olmesartan regimen or placebo- 
based regimen (on a background  
of other antihypertensive agents);  
median follow-up 3.2 years
No significant difference on the primary 
(time to first onset of microalbuminuria) or 
secondary (composite of CV complications 
or death from CV causes). A significant 
excess of CV mortality seen in the 
olmesartan arm
Studies in high-risk patients with HF
VALiANT78 Patients aged $18 years,  
with HF or left ventricular systolic  
dysfunction, or both, and prior Mi;  
n = 14,703
Valsartan monotherapy, captopril 
monotherapy, or valsartan plus 
captopril on a background of 
antihypertensive treatment;  
median follow-up 2.1 years
Equivalent efficacy for the primary endpoint 
of all-cause mortality for all three groups. 
The valsartan plus captopril group had the 
most drug-related adverse events
Val-HeFT79 Patients aged $18 years,  
with chronic HF and left  
ventricular systolic dysfunction;  
n = 5010
Valsartan monotherapy or  
placebo on a background of 
antihypertensive treatment,  
which was ACe  
inhibitors in 93% of patients;  
mean follow-up 1.9 years
Equivalent efficacy for the primary endpoint 
of all-cause mortality for the 2 groups. 
Significant reduction in the composite 
endpoint of mortality and morbidity with  
the valsartan-based regimen vs the  
placebo-based regimen, and this was  
driven by a 24% reduction in the rate  
of adjudicated hospitalizations for  
worsening HF
OPTiMAAL80 Patients aged $50 years,  
with HF or left ventricular systolic  
dysfunction, and acute Mi;  
n = 5477
Losartan monotherapy or  
captopril monotherapy on a 
background of antihypertensive 
treatment; mean follow-up  
2.7 years
Trend for superior efficacy in the captopril 
group compared with the losartan group for 
the endpoint of all-cause mortality. Losartan 
was significantly better tolerated than 
captopril, being associated with significantly 
fewer discontinuations
eLiTe ii81 Patients aged $60 years,  
with HF and left ventricular  
systolic dysfunction; n = 3152
Losartan monotherapy or  
captopril monotherapy on a  
background of antihypertensive  
treatment;  
median follow-up 1.5 years
Equivalent efficacy for the primary endpoint 
of all-cause mortality for the 2 groups. 
Losartan was significantly better tolerated 
than captopril, being associated with 
significantly fewer discontinuations
HeAAL82 Patients aged $18 years,  
with HF, left ventricular systolic  
dysfunction and known  
intolerance to ACe inhibitors;  
n = 3846
Losartan 50 mg/day vs  
150 mg/day on a background of  
antihypertensive treatment;  
median follow-up 4.7 years
Significant reduction in the primary 
composite endpoint of all-cause mortality 
and hospital admission for HF with the 
higher-dose losartan group compared with 
the lower-dose losartan group. There 
was no significant difference in the rate of 
treatment discontinuation between the 
doses
CHARM-Overall83 Patients aged $18 years,  
with HF with/without left  
ventricular systolic dysfunction;  
n = 7601
Candesartan or placebo on a 
background of antihypertensive 
treatment; median follow-up  
3.1 years
Significant reduction in the primary endpoint 
of all-cause mortality with candesartan vs 
placebo
CHARM- 
Preserved84
Patients aged $18 years,  
with HF with preserved left  
ventricular systolic function  
(ejection fraction .40%);  
n = 3023
Candesartan or placebo on a 
background of antihypertensive 
treatment; median follow-up  
3.0 years
Nonsignificant reduction in the primary 
composite endpoint of CV death or 
hospital admission for HF with candesartan 
vs placebo; the reduction was driven by 
significantly fewer candesartan-treated 
patients being hospitalized for HF
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receive either once-daily losartan-based or atenolol-based 
antihypertensive therapy for at least four years.22 The 
losartan-based regimen demonstrated a significant benefit 
over the atenolol-based regimen with respect to the 
primary composite outcome (cardiovascular mortality, 
stroke, and myocardial infarction, relative risk [RR] 0.87, 
95% confidence interval [CI] 0.77–0.98; P = 0.021). The 
primary endpoint of the LIFE trial was mostly driven by the 
clinically important and statistically significant reduction in 
stroke morbidity/mortality.22 Unfortunately, atenolol, the 
comparator in the LIFE study, has subsequently been shown 
to be no better than placebo in reducing cardiovascular 
mortality and myocardial infarction,87 but β-blockers have 
been proven to reduce stroke morbidity and mortality in 
placebo-controlled trials. Consequently, the LIFE study 
resulted in an indication of losartan for the prevention of 
stroke morbidity/mortality in hypertensive patients with left 
ventricular hypertrophy.
The Valsartan Antihypertensive Long-term Use 
Evaluation (VALUE) study recruited 15,313 patients with 
hypertension and a high risk of cardiovascular events 
based on a number of qualifying risk factors, such as 
age $50 years, verified diabetes mellitus, current smoker, 
high total cholesterol levels, and the presence of any of a 
number of other qualifying cardiovascular diseases.74 The 
study randomized the patients to receive antihypertensive 
therapy based on either valsartan or amlodipine.74 Both 
regimens reduced blood pressure, but the antihypertensive 
effects of the amlodipine-based regimen were more 
pronounced, particularly in the early stages, ie, months 
1–6 of treatment.74 In terms of the primary composite 
endpoint of cardiac mortality and morbidity, there was no 
significant difference between the two regimens (hazard 
ratio [HR] 1.04, 95% CI 0.94–1.15; P = 0.49).74 Amlodipine 
demonstrated superior efficacy in the early stage, ie, the 
first three months, of the trial compared with valsartan on 
the incidence of nonfatal myocardial infarction and stroke, 
which was most likely a blood pressure-related effect, 
while valsartan was better in preventing both heart failure 
and new-onset diabetes at the later stage, ie, 36 months and 
beyond, of the trial.74
The addition of valsartan to conventional treatment pre-
vented more cardiovascular events (angina pectoris, heart 
failure, dissecting aneurysm of the aorta, stroke/transient isch-
emic attack) than supplementary conventional treatment in 
the Jikei Heart Study.88 More recently, the Kyoto Heart Study 
demonstrated that valsartan added to conventional antihyper-
tensive therapy prevented more cardiovascular events than 
the conventional non-ARB regimen in a patient population 
similar to that of the VALUE study.75 Valsartan was associ-
ated with significantly fewer primary composite endpoints 
(fatal and nonfatal cardiovascular events) than the non-ARB 
regimen (HR 0.55, 95% CI 0.42–0.72; P = 0.00001). It is 
important to note that although the inclusion criteria were 
similar for the two studies (uncontrolled hypertension and 
additional risk factors), the hypertensive patients (n = 3031) 
included in the Kyoto Heart Study had a lower incidence of 
existing cardiovascular disease than the VALUE trial popula-
tion and their in-trial blood pressure reductions were greater. 
This study was of particular value in terms of determining 
the beyond blood pressure-lowering effects of valsartan, 
because the blood pressure reductions were closely matched 
in the two arms throughout the study.75 However, the open-
label design of the study has been criticized, particularly in 
light of the fact that the superior efficacy of valsartan was 
strongly influenced by the relatively soft endpoints of angina 
Table 2 (Continued)
Study Patient characteristics Treatments Primary outcomes
i-PReSeRVe85 Patients aged $60 years,  
with HF with preserved left  
ventricular systolic function  
(ejection fraction $45%);  
n = 4128
irbesartan or placebo on  
a background of antihypertensive 
treatment; mean follow-up  
4.1 years
No significant difference in the primary 
composite endpoint of all-cause mortality 
and hospitalization for a CV event with 
irbesartan vs placebo
Abbreviations: ABPM, ambulatory blood pressure monitoring; ACe, angiotensin-converting enzyme; AMADeO®, A trial to compare telMisartan 40 mg titrated to   
80 mg versus losArtan 50 mg titrated to 100 mg in hypertensive type 2 Diabetic patients with Overt nephropathy; ARB, angiotensin ii receptor blocker; BP, blood pressure; 
CHARM, Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity; CV, cardiovascular; DeTAiL®, Diabetics exposed to Telmisartan And enalapriL; 
ELITE-II, Evaluation of Losartan In The Elderly-II; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HEAAL, Effects of high-dose versus low-dose losartan on 
clinical outcomes in patients with heart failure; HF, heart failure; HR, hazard ratio; iDNT, irbesartan Type ii Diabetic Nephropathy Trial; i-PReSeRVe, irbesartan in HF with 
preserved eF; iRMA-2, iRbesartan in patients with type 2 diabetes and MicroAlbuminuria; LiFe, Losartan intervention For endpoint Reduction in Hypertension; LVH, left 
ventricular hypertrophy; Mi, myocardial infarction; OPTiMAAL, OPtimal Therapy in Myocardial infarction with the Angiotensin ii Antagonist Losartan; ReNAAL, Reduction 
of endpoints in NiDDM with the Angiotensin ii Antagonist Losartan; T2DM, type 2 diabetes mellitus; UAe, urinary albumin excretion; Val-HeFT, Valsartan in Heart Failure 
Trial; VALiANT, VALsartan in Acute myocardial iNfarcTion; VALUe, Valsartan Antihypertensive Long-term Use evaluation; ViVALDi®, A trial to inVestigate the efficacy of 
telmisartan versus VALsartan in hypertensive type 2 Diabetic patients with overt nephropathy.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and transient ischemic attacks, which were included in the 
composite endpoint.
Several studies have shown that ARBs are renoprotective 
in patients with symptoms of early and overt nephropathy, 
reducing the risk of further proteinuria and progression 
to end-stage renal disease. For example, the IRbesartan 
in patients with type 2 diabetes and MicroAlbuminuria 
(IRMA2) study demonstrated that the addition of irbesartan 
to a background of other antihypertensive agents delayed 
the development of diabetic nephropathy in hypertensive 
patients with type 2 diabetes and persistent microalbu-
minuria.20 In this study, the blood pressure-lowering effects 
of irbesartan were similar to those of the placebo (ie, the 
background antihypertensive therapy), supporting the theory 
that the renal effects of irbesartan were independent of blood 
pressure-lowering. Similarly, losartan added to existing 
antihypertensive therapies was found to have beneficial renal 
effects in hypertensive patients with type 2 diabetes and 
diabetic nephropathy in the Reduction of Endpoints in Non-
insulin-dependent diabetes mellitus with the Angiotensin II 
Antagonist Losartan (RENAAL) study.21 The losartan-based 
regimen was associated with a 16% reduction in the primary 
composite endpoint of a doubling of the baseline serum 
creatinine concentration, the development of end-stage renal 
disease or all-cause mortality.21 In the Irbesartan in Diabetic 
Nephropathy (IDNT) study, which compared irbesartan with 
amlodipine and placebo, all added to existing antihyperten-
sive therapies, in patients with type 2 diabetes and diabetic 
nephropathy, irbesartan significantly reduced the risk of the 
primary composite endpoint of a doubling of the baseline 
serum creatinine concentration, end-stage renal disease or 
all-cause mortality compared with amlodipine (-23%) and 
placebo (-20%).19
Cerebroprotective effects of ARBs are mostly related 
to their blood pressure-lowering effects. In patients with 
isolated systolic hypertension, candesartan significantly 
decreased incidence of stroke in a subgroup of patients 
involved in the Study on COgnition and Prognosis in the 
Elderly (SCOPE) trial.89 In the LIFE trial,90 the incidence 
of stroke was significantly lower with losartan than with 
atenolol in the broad spectrum of at-risk patients involved, 
ie, those with isolated systolic hypertension, diabetes 
mellitus, or atrial fibrillation. In patients who had already 
suffered from stroke, candesartan, initiated on the first day, 
significantly reduced the incidence of vascular event rates 
in the Evaluation of Acute Candesartan CilEexetil therapy 
in Stroke Survivors (ACCESS) trial.91 Eprosartan was more 
effective than nitrendipine in the MOrbidity and mortality 
after Stroke – Eprosartan compared with nitrendipine 
for Secondary prevention (MOSES) trial. The effect of 
telmisartan started soon after an ischemic stroke was not 
significantly different from that of placebo in lowering the 
rate of recurrent stroke and major cardiovascular events in 
the Prevention Regimen For Effectively avoiding Second 
Strokes (PRoFESS®) trial,92 most probably because the 
duration of the trial (2.5 years) was too short, and because 
of the counterbalancing effect of other antihypertensives 
reducing blood pressure.
A direct head-to-head comparison of an ACE inhibitor 
and an ARB in patients with type 2 diabetes, mild to 
moderate hypertension, and early nephropathy, the Diabetics 
Exposed to Telmisartan And enalaprIL (DETAIL®) study,24 
demonstrated equivalent efficacy for telmisartan and 
enalapril in terms of the primary endpoint of change in 
glomerular filtration rate. In contrast, telmisartan reduced 
proteinuria more than losartan in hypertensive patients with 
type 2 diabetes with overt nephropathy in A trial to compare 
telMisartan 40 mg titrated to 80 mg versus losArtan 50 mg 
titrated to 100 mg in hypertensive type 2 DiabEtic patients 
with Overt nephropathy (AMADEO®),27 despite similar blood 
pressure reductions. Telmisartan reduced proteinuria to an 
equivalent degree compared with valsartan in the inVestIgate 
the efficacy of telmIsartan versus VALsartan in hypertensive 
type 2 DIabetic patients with overt nephropathy (VIVALDI®) 
study.77 The AMADEO and VIVALDI studies used broadly 
similar designs. Therefore, the results may reflect differences 
in antiproteinuric effect between telmisartan, losartan, and 
valsartan. However, methodologic differences and variations 
between patient-related parameters (eg, use of adjuvant 
antihypertensive agents, ethnic diversity) may also explain 
why telmisartan was superior to losartan and equivalent to 
valsartan.46
Studies in high-risk patients  
with a broad range of additional  
risk factors
Patients with normal blood pressure (normotensive or 
well controlled on antihypertensive therapy) but who still 
have a high cardiovascular disease risk because of a prior 
cardiovascular event or concomitant diabetes who do not 
yet have heart failure, form a substantial population. There 
have been three studies of cardiovascular disease outcomes 
with ARBs conducted in patients at this stage of the cardio-
vascular disease continuum, and both were with telmisartan. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The first study, ONTARGET, randomized 25,620 patients 
at high cardiovascular risk with vascular disease (coronary, 
peripheral or cerebrovascular disease) or diabetes with 
end-organ damage, to receive telmisartan, the reference 
standard ACE inhibitor ramipril, or a combination of the two 
agents.28 This trial demonstrated that, in terms of the primary 
composite outcome of cardiovascular death, myocardial 
infarction, stroke, or hospitalization due to heart failure, 
telmisartan was noninferior to ramipril (RR 1.01, 95% CI 
0.94–1.09), but it was better tolerated. Because blood pres-
sure was equally controlled by the two agents, the results of 
the ONTARGET trial suggest that telmisartan, like ramipril, 
prevents cardiovascular events beyond that provided by 
blood pressure-lowering alone.28 The combination of the 
two agents was no more effective in terms of the primary 
composite outcome, but it was associated with a higher rate 
of adverse events (eg, hypotension, acute dialysis) than the 
single agents alone. The results of this trial suggest that dual 
renin-angiotensin system blockade with combinations of 
ACE inhibitors and ARBs offers no additional benefits in this 
specific patient population, while telmisartan was similarly 
effective as the established standard of ramipril.
The second study, the Telmisartan Randomized 
AssessmeNt Study in ACE-I iNtolerant subjects with 
cardiovascular Disease (TRANSCEND®) trial, ran in parallel 
with the ONTARGET trial and recruited patients who were 
not able to tolerate ACE inhibitors.29 This trial randomized 
5926 patients with cardiovascular disease or diabetes with 
end-organ damage, many of whom were receiving existing 
therapies (best standard of care), to receive either telmisartan 
or placebo. The primary composite outcome was the same as 
that for the ONTARGET trial. The addition of telmisartan 
to the existing treatment regimen resulted in lower blood 
pressure throughout the study. In terms of the primary 
composite outcome, telmisartan did not demonstrate 
significant effects compared with the best standard of care 
group (HR 0.92, 95% CI 0.81–1.05; P = 0.216). In contrast, 
the secondary composite endpoint, which, like the primary 
composite endpoint in the Heart Outcomes Prevention 
Evaluation (HOPE) study18 did not include new-onset heart 
failure, did demonstrate the beneficial effect of telmisartan 
(HR 0.87, 95% CI 0.76–1.00; P = 0.048 unadjusted).29 Also, 
the TRANSCEND trial demonstrated that significantly fewer 
patients were hospitalized for cardiovascular reasons in the 
telmisartan group than in the placebo group.
A third study, the Randomized Olmesartan and Diabetes 
Microalbuminuria Prevention (ROADMAP) trial, was a 
placebo-controlled study in patients without hypertension 
but with diabetes and at least one additional cardiovas-
cular risk factor.93 The primary endpoint was the time to 
first onset of microalbuminuria, which after adjusting for 
blood pressure differences, was nonsignificant. There was 
also no significant difference in the secondary endpoint, 
a composite of cardiovascular complications or death 
from cardiovascular causes (HR 1.00, 95% CI 0.75–1.33; 
P = 0.99). However, deaths from cardiovascular causes were 
significantly higher with olmesartan (n = 15, 0.7%) than 
with placebo (n = 3, 0.1%; HR 4.94, 95% CI 1.43–17.06; 
P = 0.01). Although the cause of this excess mortality is 
unknown, a similar excess cardiovascular mortality with 
olmesartan was also seen in the Olmesartan Reducing Inci-
dence of End Stage Renal Disease in Diabetic Nephropathy 
Trial (ORIENT).94 Therefore,   olmesartan should be used 
with caution in patients at high risk due to the presence of 
cardiovascular risk factors.
Studies in high-risk patients  
with heart failure
There have been a number of studies of ARBs in patients 
at the end of the cardiovascular disease continuum, ie, 
in patients with heart failure or left ventricular systolic 
dysfunction. The VALsartan In Acute myocardial iNfarction 
Trial (VALIANT)78 trial demonstrated equivalent efficacy 
for the primary endpoint of all-cause mortality for valsartan 
and captopril in patients with heart failure or left ventricular 
dysfunction after a recent myocardial infarction. VALIANT 
also showed little advantage in implementing dual renin-
angiotensin system blockade by administering both valsartan 
and captopril. The Valsartan HEart Failure Trial (Val-HEFT) 
demonstrated that the addition of valsartan to an existing 
antihypertensive treatment, which was mainly an ACE 
inhibitor, reduced hospital admission for worsening heart 
failure but not mortality,79 again suggesting that, in general, 
dual renin-angiotensin system blockade confers additional 
therapeutic efficacy only in a subgroup of patients not 
receiving β-blockers.93
In contrast with VALIANT, an earlier study with losartan 
50 mg/day and captopril 3 × 50 mg/day, the Evaluation 
of Losartan In The Elderly II (ELITE II) trial81 found 
equivalent efficacy for the endpoint of all-cause mortality 
and a tolerability advantage for losartan. The OPtimal 
Therapy in Myocardial Infarction with the Angiotensin II 
Antagonist Losartan (OPTIMAAL) trial80 demonstrated 
a trend (P = 0.069) of a higher efficacy of captopril over 
losartan at the same doses used in the ELITE II trial 
(3 × 50 mg/day and 50 mg/day, respectively) for the same Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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endpoint, although losartan was again significantly better 
tolerated than captopril. However, a more recent study, the 
Effects of high-dose versus low-dose losartan on clinical 
outcomes in patients with heart failure (HEAAL) study,82 
found that a three-times higher dose of losartan (150 
mg/day) was more effective than the lower dose of 50 mg/
day, suggesting that the dose of losartan was probably too 
low in both the OPTIMAAL and ELITE II trials.
The Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM) trial83 
demonstrated superior efficacy for candesartan over 
standard antihypertensive treatment in terms of deaths and 
hospital admissions, although the CHARM-Preserved trial84 
demonstrated no benefits of the addition of candesartan in 
heart failure patients who had a preserved ejection fraction. 
Similarly, the Irbesartan in Heart Failure with preserved 
EF (I-PRESERVE) trial85 found no benefit of the addition 
of irbesartan to standard antihypertensive treatment in 
patients with heart failure and a preserved ejection fraction. 
In patients with heart failure on hemodialysis, telmisartan 
added to background ACE inhibitor therapy reduced all-cause 
mortality (HR 0.51, 95% CI 0.32–0.82) compared with best 
usual care, as well as hospital admissions for congestive heart 
failure and cardiovascular deaths.96
ARB-based combination therapy
The usual approach taken in the management of hypertension 
is to initiate treatment with a single agent, which is then 
titrated to its full dose. However, because most hypertensive 
patients require combination therapy, guidelines worldwide 
now recommend initial combination therapy (including 
renin-angiotensin system inhibitors) in patients most 
likely not at goal, with monotherapy, and calcium channel 
blockers and diuretics being the preferred combination 
partners.11,13
There is evidence to support the use of low-dose com-
bination therapy to increase the blood pressure-  lowering 
efficacy of the component drugs while reducing the 
incidence of adverse events.97,98 The reduction in blood 
pressure achieved with drugs used in combination is   usually 
additive.97–99 A number of ARB-based combination therapies 
are   recommended based on the results of randomized 
efficacy trials. In the US, seven of the currently available 
eight ARBs are available in single-pill combinations with 
the thiazide diuretic, hydrochlorothiazide,10,12,13 and three 
ARBs   (valsartan, olmesartan, and telmisartan) as single-pill 
combinations with amlodipine. Among the antihypertensive 
drug classes, ACE inhibitors and ARBs are recommended for 
the largest variety of compelling indications, which for the 
ARBs include reduction of cardiovascular morbidity, heart 
failure, post-myocardial infarction, diabetic renal disease, 
proteinuria/microalbuminuria, left ventricular hypertrophy, 
atrial fibrillation, metabolic syndrome, and ACE inhibitor-
induced cough.12,13 Around 66% of the recommended dual 
antihypertensive combinations are based on ACE inhibitors 
and ARBs.12
There are few data on the reduction of cardiovascular 
endpoints beyond blood pressure-lowering with combinations 
of antihypertensive agents. In particular, there is currently no 
evidence for ARB-based combination therapy, although the 
blood pressure-lowering effects of ARBs in combination with 
thiazide diuretics and calcium channel blockers have been   
shown to be additive.100–105 An additional benefit of using an 
ARB, such as valsartan, olmesartan, or telmisartan, with the 
calcium channel blocker amlodipine is that the incidence of 
amlodipine-related edema is reduced.102–105 In contrast with 
the ARBs, there are fewer data for ACE inhibitor-based 
combinations. The Avoiding Cardiovascular Events Through 
Combination Therapy in Patients Living with Systolic 
Hypertension (ACCOMPLISH) trial investigated whether 
the ACE inhibitor benazepril 40 mg combined with the 
calcium channel blocker amlodipine 10 mg would reduce 
cardiovascular disease events more effectively than benazepril 
40 mg in combination with the diuretic hydrochlorothiazide 
25 mg.106,107 Treatment with the benazepril-amlodipine 
combination was associated with a 2.2% absolute risk 
reduction and a 19.6% relative risk reduction (HR 0.80, 
95% CI 0.72–0.90; P , 0.001) in the primary composite 
outcome of death from cardiovascular causes, nonfatal 
myocardial infarction, nonfatal stroke, hospitalization 
for angina, resuscitation after sudden cardiac arrest, and 
coronary revascularization.107 A significant risk reduction 
associated with the benazepril–amlodipine combination 
was also found for the secondary endpoint of death from 
cardiovascular causes, nonfatal myocardial infarction, and 
nonfatal stroke (HR 0.79, 95% CI 0.67  –0.92; P = 0.002), and 
for renal disease progression (HR 0.52, 95% CI 0.41–0.65; 
P , 0.0001).106,107
Safety of ARBs
Many large clinical trials have shown favorable tolerability 
of ARBs, characterizing these drugs as the safest in 
cardiovascular medicine. Some seven years ago, results 
of a published meta-analysis108 suggested that ARBs may 
increase the risk of myocardial infarction. This meta-
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and convincingly refuted by many more comprehensive 
and updated meta-analyses, taking into account all 
major international, randomized trials using ARBs 
compared with another active drug or conventional 
therapy (placebo) which reported information on rates of 
myocardial infarction. These analyses found no significant 
differences in fatal and nonfatal myocardial infarction 
among treatment with ARBs, placebo, or active treatment, 
even in those trials in which ARBs were compared with 
ACE inhibitors, or when pooling all trials together; 
the percentages of myocardial infarction in the overall 
considered populations were 5.49% for ARBs and 5.31% 
for other drugs.113–115 Recently, the ONTARGET and 
TRANSCEND trials also provided convincing evidence 
against the above criticism by showing the absence of 
a significant difference in myocardial infarction rates 
between telmisartan and ramipril and between telmisartan 
and placebo, respectively.28,29 Despite continued debate 
within the clinical community,116,117 the recent reappraisal 
of the European Society of Hypertension/European 
Society of Cardiology 2007 guidelines refers to the 
interchangeability of these two classes of drugs, the ARBs 
and ACE inhibitors, to prevent cardiovascular morbidity 
and mortality.13
Agents that inhibit the renin-angiotensin system, including 
ACE inhibitors, ARBs, and direct renin inhibitors, induce a 
compensatory rise in plasma renin by suppressing the negative 
feedback loop. Although renin levels prior to treatment 
initiation may relate to long-term cardiovascular risk,118,119 
the evidence is conflicting,120 and there is no evidence that 
a reactive increase in renin in response to antihypertensive 
treatment has any cardiovascular consequences. Based on 
evidence from randomized controlled trials, dual renin-
angiotensin system blockade with ARBs and ACE inhibitors 
is associated with significant increases in hyperkalemia, 
worsening renal function, and symptomatic hypotension.121 
These adverse events have also been seen in the community 
setting, particularly in patients with reduced renal function 
at baseline.122 As a result, patients receiving dual renin-
angiotensin system blockade should be monitored for renal 
function and serum potassium levels. Currently no evidence 
exists on the cardiovascular safety of the ARB/renin inhibitor 
combination.
An initial meta-analysis of 61,590 patients involved in 
ARB clinical trials reported an unexpected, modest increase 
in the risk of a new cancer diagnosis in patients assigned to 
receive ARBs compared with patients in control groups (7.2% 
versus 6.0%, RR 1.08, 95% CI 1.01–1.15; P = 0.016).123 
These results, significant only for lung cancer (0.9% versus 
0.7%, RR 1.25, 1.05–1.49; P = 0.01), were mainly driven by 
the combination (telmisartan-ramipril) arm of ONTARGET, 
and by the results of the LIFE and the CHARM-Overall 
studies. However, there was no increase in cancer diag-
nosis with either monotherapy (telmisartan or ramipril) in 
ONTARGET, nor with telmisartan in the TRANSCEND or 
PRoFESS studies.
The authors of this meta-analysis123 appropriately outline 
its limitations, as the trials involved were not designed to 
explore cancer outcomes, the adjudication of cancer diagno-
ses was not uniform among the included studies, the analyses 
did not include the individual patient data for any of the trials, 
did not consider the latency for the malignancies, and did 
not take into account the effect of gender, age, smoking, or 
other known risk factors for malignancies. In addition, the 
meta-analysis combined trials with different comparators, ie, 
ramipril, atenolol, and placebo. It also did not include some 
important large trials (for example, VALUE).
Subsequent meta-analyses were not able to confirm that 
ARBs are associated with increased risk of cancer. Julius et al 
included the VALUE trial and found event rates of 1870/24, 
146 (7.7%) with ARBs versus 1853/24, 123 (7.7%) with com-
parators.124 In an analysis of 70 randomized trials of ARBs, 
ACE inhibitors, β-blockers, calcium channel blockers, or 
diuretics, Bangalore et al were able to refute a 5.0%–10.0% 
relative increase in the risk of cancer or cancer-related death 
with the use of ARBs, although they were unable to rule 
out increased risk of cancer with the combination of ACE 
inhibitors and ARBs.125
The most comprehensive assessment of ARBs and 
cancer to date analyzed all trials of five ARBs (candesartan, 
irbesartan, losartan, telmisartan, and valsartan) which 
enrolled $500 patients and had $12-month follow-up 
(total 15 trials and 138,769 patients).126 The authors had 
access to individual data from ONTARGET, TRANSCEND, 
and PRoFESS and tabulated data on cancer outcomes by 
treatment allocation from all major trials of irbesartan, 
valsartan, candesartan, and losartan. There was no 
association between cancer risk and any individual ARB, 
or with ARBs overall (4549/73, 808 [6.16%] with ARBs 
versus 3856/61,106 [6.31%] non-ARB control [OR 1.00, 
95% CI 0.95–1.04]). Unlike the analysis by Sipahi et al,123 
they were able to analyze the relationship with site-specific 
cancers in all 15 trials, and found no association of ARBs 
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cancers, ie, prostate cancer and breast cancer). The authors 
had access to data from several additional trials (Atrial 
fibrillation clopidogrel trial with irbesartan for prevention 
of vascular events [ACTIVE I], I-PRESERVE, and Val-
HeFT), in which data on background ACE inhibitors in 
combination with the ARB were available, thus allowing 
comparison of the combination versus ACE inhibitor alone. 
This was in addition to the ONTARGET, VALIANT, and 
CHARM-Added trials in which patients were allocated to 
the combination or ACE inhibitor alone at randomization 
(total population 47,020). The incidence of cancer was 
5.33% for combination ARB + ACEI versus 5.26% for ACE 
inhibitors alone (OR 1.01, 95% CI 0.94–1.10). Overall, there 
was no significant difference in cancer incidence between 
combination therapy and ACE inhibitors.
Therefore, several meta-analyses, including the most 
recent one,127 using the most comprehensive data avail-
able have found no link between any ARB, or the class as 
a whole, and cancer. In addition, there is no clear mecha-
nism of action known to explain any ARB-related cancer 
link. Furthermore, from a pathophysiologic viewpoint, the 
finding in the meta-analysis of increased cancer risk with 
ARBs in such a short time period (2–4 years) is highly 
improbable, given that it takes around 10 years to develop 
lung and other cancers from smoking. A 2010 position 
paper of the Italian Society of Hypertension concluded 
that the benefits derived from the use of ARBs outweigh 
the potential risks, and that the use of these drugs should 
be maintained according to present indications.128 In June 
2011, the US Food and Drug Administration completed a 
review of the potential risk of cancer and concluded that 
treatment with an ARB medication does not increase the 
risk of developing cancer.129
Choosing the right ARB  
for an individual patient
As described in this review, it is very important to con-
sider the individual cardiovascular disease history and 
risk for further cardiovascular disease events in patients 
when considering which ARB to prescribe. All eight cur-
rently available ARBs have demonstrated efficacy in blood 
  pressure-lowering and are licensed for the treatment of 
hypertension, although there may be differences in their 
blood pressure-lowering efficacy and duration of action.130 
Clinical trials with ARBs have been conducted in patients 
at different stages of the cardiovascular and renal disease 
continua (the cardiovascular disease prevention and reno-
protection studies described here), and as a result they have 
different indications (Table 3). For example, in the US and 
Europe, olmesartan, eprosartan, and azilsartan are only 
indicated for the treatment of hypertension because they 
have not demonstrated cardiovascular disease and renal 
protective effects. Irbesartan and losartan are indicated for 
the reduction of renal disease progression in hypertensive 
patients with type 2 diabetes and diabetic renal disease. 
Based on the results of the CHARM, VALIANT, Val-HeFT, 
and HEAAL studies, candesartan and valsartan (and losartan 
in Europe) are indicated in patients with heart failure, and 
losartan is indicated for stroke prevention in hypertensive 
patients with left ventricular hypertrophy. Telmisartan is the 
only ARB indicated for cardiovascular prevention in a broad 
range of high-risk patients with or without hypertension, 
Table 3 indications for the eight currently available angiotensin receptor blockers
Azilsartan Candesartan Eprosartan Irbesartan Losartan Olmesartan Telmisartan Valsartan
Hypertension • • • • • • • •
    Hypertension and type 2 
diabetic renal disease
• •
    Prevention of stroke in 
hypertension and LVH
•
CV high risk
    T2DM with target  
organ damage
•
    Atherothrombotic  
CV disease, for example:
    Coronary heart disease •
    Peripheral arterial disease •
    Stroke •
Heart failure or left  
ventricular dysfunction
• • •
Abbreviations: CV, cardiovascular; HF, heart failure; LVH, left ventricular hypertrophy; T2DM, type 2 diabetes mellitus.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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including those with manifest atherothrombotic cardiovas-
cular disease (ie, a history of coronary heart disease, stroke, 
or peripheral arterial disease) or those with type 2 diabetes 
with documented target organ damage, based on the results 
of the ONTARGET and TRANSCEND trials.28,29
Conclusion
As effective blockers of the renin-angiotensin system, ARBs 
provide both antihypertensive and anti-inflammatory effects, 
making them an attractive and widely used therapeutic option 
for patients with or without hypertension (depending on the 
ARB) and additional cardiovascular disease risk factors or 
concomitant cardiovascular or renal diseases. Their favor-
able tolerability profiles are likely to play a key role in the 
maintenance of long-term adherence to these agents. This 
review considers the evidence from several major cardiovas-
cular outcomes studies, which have clearly demonstrated that 
treatment with ARBs is protective, reduces cardiovascular 
risk, and provides cerebral and renal protection beyond 
that achieved by blood pressure-lowering alone. Direct 
anti-inflammatory or other pleiotropic effects beyond blood 
pressure-lowering may account for some of the risk reduc-
tion with ARBs and is the subject of considerable debate. 
Furthermore, pharmacologic differences between the ARBs 
impact the cardiovascular disease prevention outcome.
The currently available ARBs have demonstrated their 
differential efficacy along the cardiovascular and renal 
disease continua from patients with hypertension and early-
stage cardiovascular disease, through patients with or without 
hypertension but at an increased cardiovascular disease risk, 
and, finally, to patients with significant cardiovascular and 
renal disease (nephropathy, left ventricular dysfunction, 
heart failure). For patients at high cardiovascular risk based 
on the results of the ONTARGET and TRANSCEND stud-
ies, telmisartan is indicated for cardiovascular prevention 
beyond that of blood pressure-lowering alone. For patients 
with hypertension and specific risk factors, losartan (stroke 
prevention in patients with left ventricular hypertrophy, or 
diabetic renal disease) and irbesartan (diabetic renal disease) 
have been shown to be effective. For patients at the highest 
cardiovascular risk, with heart failure or left ventricular dys-
function, candesartan, losartan, and valsartan are indicated.
Disclosure
Csaba Farsang has previously received fees for consultation 
and speaker honoraria from Abbott, AstraZeneca,   Boehringer 
Ingelheim, Egis Rt, Menarini, MSD, Novartis, Pfizer, 
  Richter G Rt, Sanofi-Aventis, and Servier.
References
  1.  Mathers CD, Loncar D. Projections of global mortality and burden of 
disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
  2.  Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart 
  Association Statistics Committee and Stroke Statistics Subcommittee. 
Heart disease and stroke statistics – 2010 update: a report from the 
American Heart Association. Circulation. 2010;121(7):e46–e215.
  3.  Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic 
burden of cardiovascular diseases in the enlarged European Union. Eur 
Heart J. 2006;27(13):1610–1619.
  4.  Luengo-Fernández R, Leal J, Gray A, Petersen S, Rayner M. Cost of 
cardiovascular diseases in the United Kingdom. Heart. 2006;92(10): 
1384–1389.
  5.  Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction 
and cardiovascular prevention: an update including the 2003–2004 
secondary prevention trials. Hypertens Res. 2005;28(5):385–407.
  6.  Unger T. The role of the renin-angiotensin system in the development 
of cardiovascular disease. Am J Cardiol. 2002;89(2A):3A–9A.
  7.  Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease 
  continuum validated: clinical evidence of improved patient outcomes: 
part I: Pathophysiology and clinical trial evidence (risk factors 
through stable coronary artery disease). Circulation. 2006;114(25): 
2850–2870.
  8.  Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin 
system and cardiovascular risk. Lancet. 2007;369(9568):1208–1219.
  9.  Montecucco F, Pende A, Mach F. The renin-angiotensin system 
modulates inflammatory processes in atherosclerosis: evidence from 
basic research and clinical studies. Mediators Inflamm. 2009;Article ID: 
752406.
  10.  Chobanian AV , Bakris GL, Black HR, et al; Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure. National Heart, Lung, and Blood Institute; National High 
Blood Pressure Education Program Coordinating Committee. Seventh 
report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure. Hypertension. 
2003;42(6):1206–1252.
  11.  National Institute for Health and Clinical Excellence. 2006. 
Hypertension: management of hypertension in primary care. NICE 
clinical guideline 34 (Partial update of NICE clinical guideline 18). 
Available from: http://www.nice.org.uk/CG034. Accessed April 20, 
2010.
  12.  Mancia G, De Backer G, Dominiczak A, et al; The task force for 
the management of arterial hypertension of the European Society 
of   Hypertension, The task force for the management of arterial 
hypertension of the European Society of Cardiology. Management 
of Arterial Hypertension of the European Society of Hypertension; 
European Society of Cardiology. 2007 Guidelines for the Management 
of Arterial Hypertension. Eur Heart J. 2007;28(12):1462–1536.
  13.  Mancia G, Laurent S, Agabiti-Rosei E, et al; European Society of 
Hypertension. Reappraisal of European guidelines on hyperten-
sion   management: a European Society of Hypertension Task Force 
  document. J Hypertens. 2009;27(11):2121–2158.
  14.  Solomon SD, Appelbaum E, Manning WJ, et al. Aliskiren in Left 
Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the 
direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, 
or both on left ventricular mass in patients with hypertension and left 
ventricular hypertrophy. Circulation. 2009;119(4):530–537.
  15.  Weintraub HS, Tran H, Schwartzbard A. Potential benefits of aliskiren 
beyond blood pressure reduction. Cardiol Rev. 2011;19(2):90–94.
  16.  Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease 
continuum validated: clinical evidence of improved patient outcomes: 
part II: Clinical trial evidence (acute coronary syndromes through renal 
disease) and future directions. Circulation. 2006;114(25):2871–2891.
  17.  Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of 
an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular 
events in high-risk patients. The Heart Outcomes Prevention Evaluation 
Study Investigators. N Engl J Med. 2000;342(3):145–153.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
619
ARBs in patients at high CV risk
  18.  Heart Outcomes Prevention Evaluation Study Investigators. Effects 
of ramipril on cardiovascular and microvascular outcomes in people 
with diabetes mellitus: results of the HOPE study and MICRO-HOPE 
substudy. Lancet. 2000;355(9200):253–259.
  19.  Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. 
Renoprotective effect of the angiotensin-receptor antagonist irbesartan 
in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 
345(12):851–860.
  20.  Parving  HH,  Lehnert  H,  Bröchner-Mortensen  J,  Gomis  R, 
  Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes 
and Microalbuminuria Study Group. The effect of irbesartan on the 
  development of diabetic nephropathy in patients with type 2 diabetes. 
N Engl J Med. 2001;345(12):870–878.
  21.  Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study 
Investigators: Effects of losartan on renal and cardiovascular outcomes 
in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 
345(12):861–869.
  22.  Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. 
  Cardiovascular morbidity and mortality in the Losartan Intervention 
For Endpoint reduction in hypertension study (LIFE): a randomised 
trial against atenolol. Lancet. 2002;359(9311):995–1003.
  23.  Fox KM; EURopean trial On reduction of cardiac events with 
  Perindopril in stable coronary Artery disease Investigators. Efficacy 
of perindopril in reduction of cardiovascular events among patients 
with stable coronary artery disease: randomised, double-blind, placebo-
controlled, multicentre trial (the EUROPA study). Lancet. 2003; 
362(9386):782–788.
  24.  Barnett AH, Bain SC, Bouter P, et al; Diabetics Exposed to Telmisartan 
and Enalapril Study Group. Angiotensin-receptor blockade versus 
converting-enzyme inhibition in type 2 diabetes and nephropathy.   
N Engl J Med. 2004;351(19):1952–1961.
  25.  Poulter NR, Wedel H, Dahlöf B, et al; ASCOT Investigators. Role of 
blood pressure and other variables in the differential cardiovascular 
event rates noted in the Anglo-Scandinavian Cardiac Outcomes 
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005; 
366(9489):907–913.
  26.  Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention 
of cardiovascular events with an antihypertensive regimen of amlodipine 
adding perindopril as required versus atenolol adding bendroflume-
thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes 
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre 
randomised controlled trial. Lancet. 2005;366(9489):895–906.
  27.  Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study 
Investigators. Telmisartan is more effective than losartan in reducing 
proteinuria in patients with diabetic nephropathy. Kidney Int. 2008; 
74(3):364–369.
  28.  ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. 
Telmisartan, ramipril, or both in patients at high risk for vascular events. 
N Engl J Med. 2008;358(15):1547–1559.
  29.  Yusuf S, Teo K, Anderson C, et al; Telmisartan Randomised Assessment 
Study in ACE Intolerant Subjects with Cardiovascular Disease 
  (TRANSCEND) Investigators. Effects of the angiotensin-receptor 
blocker telmisartan on cardiovascular events in high-risk patients 
intolerant to angiotensin-converting enzyme inhibitors: a randomised 
controlled trial. Lancet. 2008;372(9644):1174–1183.
  30.  Hanon S, Vijayaraman P, Sonnenblick EH, Le Jemtel TH.   Persistent 
formation of angiotensin II despite treatment with maximally 
recommended doses of angiotensin converting enzyme inhibitors in 
patients with chronic heart failure. J Renin Angiotensin Aldosterone 
Syst. 2000;1(2):147–150.
  31.  Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect 
of angiotensin-converting enzyme inhibitor imidapril on vascular injury. 
Hypertension. 2003;42(4):542–547.
  32.  Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. 
N Engl J Med. 2002;347(8):621–622.
  33.  Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter 
of love and hate. Peptides. 2005;26(8):1401–1409.
  34.  Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs 
in the prevention of cardiovascular disease: meta-analysis of 147 
randomised trials in the context of expectations from prospective 
epidemiological studies. BMJ. 2009;338:b1665.
  35.  Ong HT. Are angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers especially useful for cardiovascular protection? J Am 
Board Fam Med. 2009;22(6):686–697.
  36.  Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced 
cough: ACCP evidence-based clinical practice guidelines. Chest. 2006; 
129(1 Suppl):169S–173S.
  37.  Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P,   Lillienfeld DE. 
Angioedema incidence in US veterans initiating angiotensin-converting 
enzyme inhibitors. Hypertension. 2008;51(6):1624–1630.
  38.  Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors 
and angioedema: estimating the risk. Hypertension. 2008;51(6): 
1465–1467.
  39.  Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors 
for adverse drug events associated with angiotensin-converting enzyme 
inhibitors. J Eval Clin Pract. 2004;10(4):499–509.
  40.  Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: 
comparative effectiveness of angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers for treating essential hypertension. 
Ann Intern Med. 2008;148(1):16–29.
  41.  Chaput AJ. Persistency with angiotensin receptor blockers (ARB) versus 
other antihypertensives (AHT) using the Saskatchewan database. Can 
J Cardiol. 2000;16 Suppl F:194A.
  42.  Ries UJ, Mihm G, Narr B, et al. 6-Substituted benzimidazoles as new 
nonpeptide angiotensin II receptor antagonists: synthesis, biological 
activity, and structure-activity relationships. J Med Chem. 1993;36(25): 
4040–4051.
  43.  Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-
receptor blockers independent of the renin-angiotensin system. Am J 
Hypertens. 2008;21(8):852–859.
  44.  de la Sierra A, Ram CV . Introduction: The pharmacological profile of 
eprosartan – implications for cerebrovascular and cardiovascular risk 
reduction. Curr Med Res Opin. 2007;23 Suppl 5:S1–S3.
  45.  Song JC, White CM. Olmesartan medoxomil (CS-866). An 
angiotensin II receptor blocker for treatment of hypertension. 
  Formulary. 2001;35: 487–499.
  46.  Burnier M. Telmisartan: a different angiotensin II receptor blocker pro-
tecting a different population? J Int Med Res. 2009;37(6):1662–1679.
  47.  Edarbi Prescribing Information (FDA). Revised April 2011. 
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2011/200796s001lbl.pdf. Accessed August 4, 2011.
  48.  Asmar R. Targeting effective blood pressure control with angiotensin 
receptor blockers. Int J Clin Pract. 2006;60(3):315–320.
  49.  Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the 
strongest binding affinity to angiotensin II type 1 receptor: comparison 
with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol 
Res. 2005;25(1):41–46.
  50.  Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a 
new angiotensin type 1 receptor blocker, azilsartan, in receptor binding 
and function studies. J Pharmacol Exp Ther. 2011;336(3):801–808.
  51.  Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: 
a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc 
Drug Rev. 2000;18:127–154.
  52.  Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 
2000;355(9204):637–645.
  53.  Brunner HR. The new oral angiotensin II antagonist olmesartan 
medoxomil: a concise overview. J Hum Hypertens. 2002;16 Suppl 2: 
S13–S16.
  54.  Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1)   receptor 
blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1: 
S73–S86.
  55.  Stangier J, Su CA, Fraunhofer A, Tetzloff W. Pharmacokinetics of 
acetaminophen and ibuprofen when coadministered with telmisartan in 
healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1338–1346.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
620
Farsang
  56.  Unger T, Kaschina E. Drug interactions with angiotensin receptor 
blockers: a comparison with other antihypertensives. Drug Saf. 2003; 
26(10):707–720.
  57.  Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan   
as a unique angiotensin II receptor antagonist with selective PPARgamma-
modulating activity. Hypertension. 2004;43(5):993–1002.
  58.  French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, 
azilsartan medoxomil (TAK-491), suppresses vascular wall expression 
of plasminogen activator inhibitor type-I protein potentially facilitating 
the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol. 
2011;58(2):143–148.
  59.  Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan 
suppresses chronic renal inflammation by a novel antioxidant   
action independent of AT1R blockade. Kidney Int. 2008;74(9): 
1128–1138.
  60.  Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan 
via the inhibition of urate transporter 1 (URAT 1) in hypertensive 
patients. Am J Hypertens. 2008;21(10):1157–1162.
  61.  Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and 
effects of losartan. Curr Med Res Opin. 2004;20(3):369–379.
  62.  Høieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group. 
The impact of serum uric acid on cardiovascular outcomes in the LIFE 
study. Kidney Int. 2004;65(3):1041–1049.
  63.  Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive 
activity of angiotensin II AT1 receptor antagonists: a systematic review 
of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 
2007;25(7):1327–1336.
  64.  Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative 
efficacy of olmesartan, losartan, valsartan, and irbesartan in the control 
of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5): 
283–291.
  65.  Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood 
pressure monitoring to assess antihypertensive efficacy: a comparison 
of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. 
Am J Cardiovasc Drugs. 2005;5(1):41–50.
  66.  Weir MR, Punzi HA, Flack JM, et al. A randomized, double-blind, 
forced-titration study to compare olmesartan medoxomil versus losartan 
potassium in patients with stage 1 and 2 hypertension. Postgrad Med. 
2011;123(1):80–87.
  67.  Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of 
increasing doses of olmesartan medoxomil, losartan potassium, and 
valsartan in patients with essential hypertension. J Clin Hypertens 
(Greenwich). 2007;9(3):187–195.
  68.  Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy 
of valsartan and olmesartan in mild-to-moderate hypertension: results 
of 24-hour ambulatory blood pressure monitoring. Adv Ther. 2005; 
22(1):32–43.
  69.  Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of 
telmisartan and olmesartan on home blood pressure, glucose, and 
lipid profiles in patients with hypertension, chronic heart failure, and 
metabolic syndrome. Hypertens Res. 2008;31(5):921–929.
  70.  de Luis DA, Conde R, González-Sagrado M, et al. Effects of   telmisartan 
vs olmesartan on metabolic parameters, insulin resistance and 
  adipocytokines in hypertensive obese patients. Nutr Hosp. 2010;25(2): 
275–279.
  71.  Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan 
medoxomil and olmesartan on ambulatory and clinic blood pressure.   
J Clin Hypertens (Greenwich). 2011;13(2):81–88.
  72.  White WB, Weber MA, Sica D, et al. Effects of the angiotensin 
receptor blocker azilsartan medoxomil versus olmesartan and valsar-
tan on ambulatory and clinic blood pressure in patients with stages 1 
and 2 hypertension. Hypertension. 2011;57(3):413–420.
  73.  Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes 
in drug therapy for hypertension among newly-treated patients:   
a population-based study in Italy. J Hypertens. 2008;26(4): 
819–824.
  74.  Julius S, Kjeldsen SE, Weber M, et al; VALUE Trial Group.   Outcomes 
in hypertensive patients at high cardiovascular risk treated with 
  regimens based on valsartan or amlodipine: the VALUE randomised 
trial. Lancet. 2004;363(9426):2022–2031.
  75.  Sawada T, Yamada H, Dahlöf B, Matsubara H; Kyoto Heart Study 
Group. Effects of valsartan on morbidity and mortality in uncontrolled 
hypertensive patients with high cardiovascular risks: Kyoto Heart Study. 
Eur Heart J. 2009;30(20):2461–2469.
  76.  Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, 
  Parving HH; Irbesartan in Patients with Type 2 Diabetes and Microal-
buminuria Study. Comparative effects of irbesartan on ambulatory and 
office blood pressure: a substudy of ambulatory blood pressure from 
the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria 
study. Diabetes Care. 2003;26(3):569–574.
  77.  Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI 
investigators. Antiproteinuric effects of angiotensin receptor blockers: 
telmisartan versus valsartan in hypertensive patients with type 2 
  diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 
2008;23(10):3174–3183.
  78.  Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute 
Myocardial Infarction Trial Investigators. Valsartan, captopril, or both 
in myocardial infarction complicated by heart failure, left ventricular 
dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
  79.  Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators.   
A randomized trial of the angiotensin-receptor blocker valsartan in 
chronic heart failure. N Engl J Med. 2001;345(23):1667–1675.
  80.  Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the 
OPTIMAAL Study Group. Effects of losartan and captopril on mortality 
and morbidity in high-risk patients after acute myocardial infarction: the 
OPTIMAAL randomised trial. Optimal Trial in Myocardial   Infarction 
with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335): 
752–760.
  81.  Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared 
with captopril on mortality in patients with symptomatic heart failure: 
randomised trial – the Losartan Heart Failure Survival Study ELITE II. 
Lancet. 2000;355(9215):1582–1587.
  82.  Konstam MA, Neaton JD, Dickstein K, et al; HEAAL Investigators. 
Effects of high-dose versus low-dose losartan on clinical outcomes in 
patients with heart failure (HEAAL study): a randomised, double-blind 
trial. Lancet. 2009;374(9704):1840–1848.
  83.  Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators 
and Committees. Effects of candesartan on mortality and morbidity in 
patients with chronic heart failure: the CHARM-Overall programme. 
Lancet. 2003;362(9386):759–766.
  84.  Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and 
Committees. Effects of candesartan in patients with chronic heart failure 
and preserved left-ventricular ejection fraction: the CHARM-Preserved 
Trial. Lancet. 2003;362(9386):777–781.
  85.  Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators. 
Irbesartan in patients with heart failure and preserved ejection fraction. 
N Engl J Med. 2008;359(23):2456–2467.
  86.  Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, 
Redfield MM. Trends in prevalence and outcome of heart failure with 
preserved ejection fraction. N Engl J Med. 2006;355(3):251–259.
  87.  Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: 
is it a wise choice? Lancet. 2004;364(9446):1684–1689.
  88.  Mochizuki S, Dahlöf B, Shimizu M, et al; Jikei Heart Study Group. 
Valsartan in a Japanese population with hypertension and other 
  cardiovascular disease (Jikei Heart Study): a randomised, open-label, 
blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571): 
1431–1439.
  89.  Papademetriu V , Farsang C, Elmfeld D, et al; Study on Cognition 
and Prognosis in the Elderly study group. Stroke prevention with the 
angiotensin II type 1-receptor blocker candesartan in elderly patients with 
isolated systolic hypertension: the Study on Cognition and Prognosis in 
the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–1180.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
621
ARBs in patients at high CV risk
  90.  Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive 
adults with cardiac hypertrophy randomized to losartan versus atenolol: 
the Losartan Intervention For Endpoint reduction in hypertension 
study. Hypertension. 2005;45(1):46–52.
  91.  Schrader J, Lüders S, Kulschewski A, et al; Acute Candesartan 
Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS 
Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke 
Survivors. Stroke. 2003;34(7):1699–1703.
  92.  Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. 
Telmisartan to prevent recurrent stroke and cardiovascular events.   
N Engl J Med. 2008;359(12):1225–1237.
  93.  Haller H, Ito S, Izzo JL, et al; ROADMAP Trial Investigators. 
  Olmesartan for the delay or prevention of microalbuminuria in Type 
2 diabetes. N Engl J Med. 2011;364(10):907–917.
  94.  Food and Drug Administration. FDA drug safety communication: 
ongoing safety review of Benicar and cardiovascular events. June 11, 
2010. Available from: http://www.fda.gov/Drugs/DrugSafety/  Postma
rketDrugSafetyInformationforPatientsandProviders/ucm215222.htm. 
Accessed July 28, 2011.
  95.  Krum H, Carson P, Farsang C, et al. Effect of valsartan added to 
background ACE inhibitor therapy in patients with heart failure: results 
from VAL-HeFT. Eur J Heart Fail. 2004;6(7):937–945.
  96.  Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to 
angiotensin-converting enzyme inhibitors on mortality and morbidity 
in hemodialysis patients with chronic heart failure. J Am Coll Cardiol. 
2010;56(21):1701–1708.
  97.  Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose 
combination treatment with blood pressure lowering drugs: analysis 
of 354 randomised trials. BMJ. 2003;326(7404):1427.
  98.  Farsang C, Naditch-Brule L, Avogaro A, et al. Where are we with the 
management of hypertension? From science to clinical practice. J Clin 
Hypertens (Greenwich). 2009;11(2):66–73.
  99.  Bisognano JD, McLaughlin T, Roberts CS, Tang SS. Calcium channel 
blockers, angiotensin receptor blockers, and angiotensin-converting 
enzyme inhibitors: effectiveness in combination with diuretics or 
beta-blockers for treating hypertension. Vasc Health Risk Manag. 
2007;3(5):579–585.
  100.  Mengden T, Uen S, Bramlage P. Management of   hypertension with fixed 
dose combinations of candesartan cilexetil and hydrochlorothiazide: 
patient perspectives and clinical utility. Vasc Health Risk Manag. 2009; 
5:1043–1058.
  101.  Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination 
therapy versus monotherapy in reducing blood pressure: meta-  analysis 
on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 
290–300.
  102.  Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. 
Efficacy of the combination of amlodipine and valsartan in patients 
with hypertension uncontrolled with previous monotherapy: the 
Exforge in Failure after Single Therapy (EX-FAST) study. J Clin 
Hypertens (Greenwich). 2008;10(3):185–194.
  103.  Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combina-
tion of olmesartan medoxomil and amlodipine besylate in controlling 
high blood pressure: COACH, a randomized, double-blind, placebo-
controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008; 
30(4):587–604.
  104.  Littlejohn TW 3rd, Majul CR, Olvera R, et al; Study Investigators. 
Results of treatment with telmisartan-amlodipine in hypertensive 
patients. J Clin Hypertens (Greenwich). 2009;11(4):207–213.
  105.  Littlejohn TW 3rd, Majul CR, Olvera R, et al; Study Investigators. 
Telmisartan plus amlodipine in patients with moderate or severe 
hypertension: results from a subgroup analysis of a randomized, 
placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad 
Med. 2009;121(2):5–14.
  106.  Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial 
  Investigators. Benazepril plus amlodipine or hydrochlorothiazide 
for hypertension in high-risk patients. N Engl J Med. 2008;359(23): 
2417–2428.
  107.  Bakris GL, Sarafidis PA, Weir MR, et al; ACCOMPLISH Trial 
investigators. Renal outcomes with different fixed-dose combination 
therapies in patients with hypertension at high risk for cardiovascular 
events (ACCOMPLISH): a prespecified secondary analysis of a 
  randomised controlled trial. Lancet. 2010;375(9721):1173–1181.
  108.  Verma S, Strauss M. Angiotensin receptor blockers and myocardial 
infarction. BMJ. 2004;329(7477):1248–1249.
  109.  de Kare-Silver N. Angiotensin medications and MI. Rapid response 
published in BMJ, December 3, 2004. Available from: http://bmj.
bmjjournals.com/cgi/eletters/329/7477/1248. Accessed October 7, 
2010.
  110.  McMurray JJ, Swedberg K, Pfeffer M, et al. Angiotensin receptor 
blockers and myocardial infarction. Rapid response published in BMJ, 
December 7, 2004. Available from: http://bmj.bmjjournals.com/cgi/
eletters/329/7477/1248. Accessed October 7, 2010.
  111.  Opie LH. ARBs: re-examine the data. Rapid response published in 
BMJ, December 9, 2004. Available from: http://bmj.bmjjournals.com/
cgi/eletters/329/7477/1248. Accessed July 19, 2005.
  112.  Taal MW, Fluck RJ, McIntyre CW. No consistent evidence that ARBs 
increase myocardial infarction. Available from: http://bmj.bmjjournals.
com/cgi/eletters/329/7477/1248. Accessed October 7, 2010.
  113.  Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, 
Weingarten SR. Meta-analysis: angiotensin AT1 receptor blockers in 
chronic heart failure and high risk acute myocardial infarction. Ann 
Intern Med. 2004;141(9):693–704.
  114.  Verdecchia P, Angeli F, Gattobigio R, Reboldi G. Do   angiotensin II 
receptor blockers increase the risk of myocardial infarction. Eur Heart J. 
2005;26(22):2381–2386.
  115.  Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and 
myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23(12): 
2113–2118.
  116.  Strauss MH, Hall AS. Angiotensin receptor blockers may increase 
risk of myocardial infarction: unraveling the ARB-MI paradox. 
Circulation. 2006;114(8):838–854.
  117.  Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not 
increase risk of myocardial infarction. Circulation. 2006;114(8): 
855–860.
  118.  Gonzalez M, Alderman M, Cohen H, Sealey J, Laragh J. Long-term 
associations of plasma renin activity with all-cause and cardiovascular 
mortality. J Hypertens. 2011;29(e-Suppl A):e17 (Abstr LB1.1).
  119.  Masson S, Solomon S, Angelici L, et al; Val-Heft Investigators. 
Elevated plasma renin activity predicts adverse outcome in chronic 
heart failure, independently of pharmacologic therapy: data from the 
Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2010;16(12): 
964–970.
  120.  Chan C, Poulter N, Scanlon M, et al; ASCOT Investigators. The 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Biomarker 
Programme. J Hypertens. 2011;29(e-Suppl A):e17 (Abstr LB1.3).
  121.  Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. 
Adverse effects of combination angiotensin II receptor blockers 
plus angiotensin-converting enzyme inhibitors for left ventricular 
dysfunction: a quantitative review of data from randomized clinical 
trials. Arch Intern Med. 2007;167(18):1930–1936.
  122.  Kurnik D, Vesterman-Landes J, Bialik M, et al. Hyperkalemia and renal 
function during monotherapy and dual renin-angiotensin blockade in 
the community setting. Clin Ther. 2011;33(4):456–464.
  123.  Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-
receptor blockade and risk of cancer: meta-analysis of randomized 
controlled trials. Lancet Oncol. 2010;11(7):627–636.
  124.  Julius S, Kjeldsen S, Weber M. Angiotensin-receptor blockade and the 
risk of cancer. Omission of VALUE trial data invalidates conclusions. 
Lancet Oncol. 2010;11(9):820–821.
  125.  Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and 
risk of cancer: network meta-analyses and trial sequential analyses 
of 324 168 participants from randomised trials. Lancet Oncol. 2010; 
12(1):65–82.Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
622
Farsang
  126.  ARB Trialists Collaboration. Effects of telmisartan, irbesartan, 
valsartan, candesartan and losartan on cancers in 15 trials enrolling 
138,769 individuals. J Hypertens. 2011;29(4):623–635.
  127.  Siragy HM. A current evaluation of the safety of angiotensin receptor 
blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011; 
7:297–313.
  128.  Volpe M, Morganti A; Executive Committee of the Italian   Society 
of Hypertension. 2010 position paper of the Italian Society of 
Hypertension (SIIA): angiotensin receptor blockers and risk of cancer. 
High Blood Press Cardiovasc Prev. 2011;18(1):37–40.
  129.  FDA Drug Safety Communication. No increase in risk of cancer with 
certain blood pressure drugs: Angiotensin Receptor Blockers (ARBs). 
June 2, 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/
ucm257516.htm. Accessed June 9, 2011.
  130.  Farsang C, Fischer J. Optimizing antihypertensive therapy by 
angiotensin receptor blockers. In: Fischer J, Ganellin CR, editors. 
Analogue-Based Drug Discovery. Weinheim, Germany: Wiley-VCH; 
2006.